Mark Velleca, M.D., Ph.D.

Dr. Mark Velleca is currently the CEO and Chairman of the Board of Black Diamond Therapeutics (BDTX), and also serves as Board Chair of iOnctura. Mark served as CEO of G1 Therapeutics (GTHX) until 2021, where he took the company public and led the development of its first therapy (COSELA®) from IND filing to FDA approval. Previously, Mark was Executive Vice President at the Leukemia & Lymphoma Society (LLS). Prior to LLS, Mark was a co-founder and Senior Vice President of CGI Pharmaceuticals, where he managed the company from its inception through clinical trials of multiple drug candidates. After Gilead Sciences acquired CGI, he served as a Senior Advisor to Gilead in R&D Strategy and Corporate Development. Most recently, Mark was a Venture Partner at Hatteras Venture Partners and served as CEO of StrideBio, a Hatteras portfolio company.

Earlier in his career, Mark was an attending physician at Yale New Haven Hospital and on the faculty of the Yale University School of Medicine. Mark earned an M.D. and Ph.D. from Washington University in St. Louis, and a B.S. from Yale University.